Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012 The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA .e /viagra-levitra-och-cialis.html . Suppression of antitumor immune metastasis and response. ‘Trabedersen shows excellent security and encouraging survival outcomes in individuals with advanced solid tumors’, concludes Dr. Hubert Heinrichs, Chief Medical Officer at Antisense Pharma. ‘Compared to current remedies for past due stage pancreatic carcinoma or malignant melanoma, our compound may end up being an extremely novel and attractive therapeutic alternative.’..
The most typical side effects were somnolence , asthenia , and anxiety .. Antiepileptic drug levetiracetam shown to help chronic daily headaches The antiepileptic medication levetiracetam ) considerably reduced the frequency and impact of headaches in patients identified as having transformed migraine, according to a new study presented today at the 56th annual meeting of the American Academy of Neurology . The study is among the first to evaluate a daily medication for preventing transformed migraine specifically, probably the most common types of persistent daily headache and one which can have a significant, negative impact on a person’s ability to function and their quality of life.